A Randomized Phase III Study of Arfolitixorin versus Leucovorin with 5-Fluorouracil, Oxaliplatin, and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer: The AGENT Trial.

Cancer Res Commun · 2024 · PMC10765772 · PMID 38059497

Europe PMC DOI

hedged sentence

0.4800

closest p · 9.6× alpha

0.4800

boldest claim

The sentences

did not reach statistical significanceP = 0.48not close (p > 0.1)

Exploratory Analyses The median RFS was numerically higher for arfolitixorin, but the difference did not reach statistical significance [10.6 months for arfolitixorin and 5.6 months for leucovorin, HR = 0.97 (95% CI: 0.28−3.31); one-sided P = 0.48] ( Supplementary Table S13 ; Supplementary Fig.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.